MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.7248 -0.0410 (-5.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
News headline image
Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures ↗
Lexaria Bioscience Corp (NASDAQ: LEXX) has commenced a new study to compare the effectiveness of Epidiolex to DehydraTECH-cannabidiol (CBD) for reducing seizure... 
Via Benzinga
News headline image
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
- New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses
Via CannabisNewsWire
News headline image
Lexaria Bioscience Corp.'s DehydraTECH(TM) Addresses the Needs of Medical THC Users ↗
Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that the technology required a shorter time to deliver... 
Via Benzinga
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users
Via CannabisNewsWire
New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology as an Alternative to Smoking and Vaping
Via Investor Brand Network
Topics Cannabis
Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Reveals Effectiveness of Proprietary Drug-Development Tech
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Reveals Effectiveness of Proprietary Drug-Development Tech
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Impacting the Pharmaceutical Industry
Via CannabisNewsWire
Topics Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Impacting the Pharmaceutical Industry
Via Investor Brand Network
Topics Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
Via CannabisNewsWire
Topics Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
Via Investor Brand Network
Topics Cannabis
News headline image
Lexaria's Technology Proven to Deliver Oral THC More Effectively
- DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes KELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Cannabis Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Outcome of NIC-A21-1 Study Using DehydraTECH(TM)-Nicotine Pouches
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Oral Drug Use Technology Nets Zacks Research Coverage
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Outstanding Results of Oral Nicotine Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Outstanding Results of Oral Nicotine Study
Via CannabisNewsWire
News headline image
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
- DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls - Peak levels achieved were up to 10x higher than controls KELOWNA, BC / ACCESSWIRE / October 5, 2021 /... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats
Via CannabisNewsWire
CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enhancing Performance of Antiviral Drugs, CBD
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery
Via CannabisNewsWire
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story